Business Description
electroCore, Inc. is a commercial-phase medical device enterprise whose focus lies in developing and bringing to market a variety of non-invasive vagus nerve stimulation (nVNS) therapies. Currently, the firm is advancing gammaCore, a prescription-only nVNS therapy specifically engineered for adults to acutely treat the discomfort associated with both migraine and episodic cluster headaches. Its flagship offering, the gammaCore Sapphire, is a portable, rechargeable, and refillable device intended for either regular or intermittent use over many years. Established in 2005, its corporate headquarters are situated in Rockaway, New Jersey.
Business History
Price History (1 Year)
Revenue & Net Income Trend
| Period | Revenue | Net Income | Net Margin | YoY/QoQ |
|---|
Key Metrics
EPS (Diluted): -1.65
Total Equity: -$1.71M
Shares: 8,483,000
Total Debt: $6.61M
Cash: $7.04M
EBITDA: -$11.70M
Total Debt: $6.61M
Cash: $7.04M
Revenue: $32.03M
Shares: 8,483,000
Revenue: $32.03M
Revenue: $32.03M
Revenue: $32.03M
Total Equity: -$1.71M
Tax Rate: 0.0%
Equity: -$1.71M
Total Debt: $6.61M
Cash: $7.04M
Current Liabilities: $11.35M
Long-Term Debt: $6.61M
Total Debt: $6.61M
Total Equity: -$1.71M
Shares: 8,483,000
Shares: 8,483,000
CapEx: -$66,000
Shares: 8,483,000
Stock Price: $7.84
Net Income: -$13.97M
Industry Benchmarks
Deep Analysis
Pre-flight intelligence scans the company first, then routes to the right analytical methods.
Income Statement (Annual)
Last updated: Jun 24, 2026 8:11am (3d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $5.5M | $8.6M | $16.0M | $25.2M | $32.0M |
| Cost of Revenue | $1.4M | $1.6M | $2.8M | $3.8M | $4.2M |
| Gross Profit | $4.1M | $7.0M | $13.2M | $21.4M | $27.8M |
| Operating Expenses | $24.1M | $29.9M | $32.0M | $33.6M | $40.9M |
| Operating Income | -$20.0M | -$22.9M | -$18.8M | -$12.2M | -$13.2M |
| Net Income | -$17.2M | -$22.2M | -$18.8M | -$11.9M | -$14.0M |
| EBITDA | -$17.7M | -$22.0M | -$17.8M | -$10.7M | -$11.7M |
| EPS | $-4.36 | $-4.69 | $-3.42 | $-1.59 | $-1.65 |
| EPS (Diluted) | — | — | — | — | — |
Balance Sheet (Annual)
Last updated: Jun 24, 2026 8:11am (3d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $34.7M | $17.7M | $10.3M | $3.5M | $7.0M |
| Total Current Assets | $37.5M | $21.2M | $14.3M | $16.3M | $11.6M |
| Total Assets | $42.8M | $24.8M | $16.1M | $20.5M | $18.7M |
| Current Liabilities | $5.5M | $7.0M | $8.1M | $9.2M | $11.3M |
| Long-Term Debt | $0 | $0 | $0 | $0 | $6.6M |
| Total Liabilities | $6.2M | $7.7M | $8.7M | $12.9M | $20.4M |
| Total Equity | $36.6M | $17.1M | $7.4M | $7.5M | -$1.7M |
| Retained Earnings | -$124.2M | -$146.4M | -$165.2M | -$177.1M | -$191.1M |
Cash Flow (Annual)
Last updated: Jun 24, 2026 8:11am (3d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | -$13.6M | -$16.6M | -$14.7M | -$6.9M | -$8.2M |
| Capital Expenditure | $0 | $0 | $-206,000 | $0 | $-66,000 |
| Free Cash Flow | -$13.6M | -$16.6M | -$14.9M | -$6.9M | -$8.3M |
| Acquisitions (net) | $0 | $0 | $0 | $0 | $0 |
| Debt Repayment | — | — | — | — | — |
| Dividends Paid | — | — | — | — | — |
| Stock Buybacks | $0 | $0 | $0 | $0 | $0 |
| Net Change in Cash | $30.4M | -$16.7M | -$7.4M | -$6.9M | $3.3M |
Analyst Estimates (Annual)
Last updated: Jun 26, 2026 6:59pm (13h ago)| Metric | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|
| Revenue |
$53.9M $52.6M – $55.2M
|
$70.0M $69.6M – $70.4M
|
$74.8M $72.5M – $77.3M
|
$87.0M $84.4M – $90.0M
|
| EBITDA |
-$40.9M -$41.9M – -$39.9M
|
-$53.1M -$53.4M – -$52.8M
|
-$56.7M -$58.6M – -$55.0M
|
-$66.0M -$68.3M – -$64.0M
|
| Net Income |
-$3.6M -$4.1M – -$3.1M
|
$4.6M -$1.2M – $10.7M
|
$3.1M $2.9M – $3.2M
|
$7.6M $7.3M – $8.0M
|
| EPS | — | — | — | — |
Growth Trends (YoY %)
Last updated: Jun 24, 2026 8:11am (3d ago)| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue Growth | +57.6% | +86.6% | +57.1% | +27.2% |
| Gross Profit Growth | +71.6% | +89.6% | +61.8% | +29.9% |
| Operating Income Growth | -14.1% | +17.8% | +35.3% | -8.1% |
| Net Income Growth | -28.7% | +15.0% | +36.9% | -17.5% |
| EBITDA Growth | -24.4% | +19.3% | +39.6% | -9.1% |
Insider Trading (Recent)
Last updated: Jun 27, 2026 5:36am (3h ago)All SEC Form 4 codes
- P Purchase
- Open-market or private purchase of shares.
- S Sale
- Open-market or private sale of shares.
- A Award / grant
- Grant or award of securities (RSUs, options, etc.) under Rule 16b-3.
- D Return to issuer
- Securities disposed back to the company under Rule 16b-3.
- F In-kind (tax)
- Shares withheld or delivered to pay the option-exercise price or tax — not an open-market sale.
- I Discretionary
- Discretionary transaction under an employee plan — Rule 16b-3(f).
- M Option exercise
- Exercise or conversion of a derivative (option/RSU) into shares — exempt.
- C Conversion
- Conversion of a derivative security into the underlying shares.
- E Short expiration
- Expiration of a short derivative position.
- H Long expiration
- Expiration or cancellation of a long derivative position with value received.
- O OTM exercise
- Exercise of an out-of-the-money derivative.
- X ITM exercise
- Exercise of an in-the-money or at-the-money derivative.
- G Gift
- Bona fide gift of securities.
- L Small acquisition
- Small acquisition under Rule 16a-6.
- W Inheritance
- Acquisition or disposition by will or the laws of descent.
- Z Voting trust
- Deposit into or withdrawal from a voting trust.
- J Other
- Other acquisition or disposition (explained in a Form 4 footnote).
- K Equity swap
- Transaction in an equity swap or similar instrument.
- U Tender / buyout
- Disposition via tender of shares in a change-of-control transaction.
Compensation-plan codes (A, D, F, M) are routine and rarely directional. Open-market P (buy) and S (sale) carry the most signal.
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| 2026-05-28 | Lev Joshua S. | S-Sale | 6,667.00 | $9.00 | $60,003 |
| 2026-05-21 | Errico Thomas J. | P-Purchase | 9,992.00 | $5.99 | $59,852 |
| 2026-05-20 | Errico Thomas J. | L-Small | 8.00 | $5.98 | $48 |
| 2026-05-22 | Lev Joshua S. | S-Sale | 3,000.00 | $6.50 | $19,500 |
| 2026-04-13 | Fox Michael | A-Award | 70,000.00 | $0.00 | $0 |
| 2026-04-10 | Goldberger Daniel S | S-Sale | 16,072.00 | $6.02 | $96,753 |
| 2026-04-13 | Fox Michael | 0.00 | $0.00 | $0 | |
| 2026-04-01 | Lev Joshua S. | A-Award | 45,000.00 | $0.00 | $0 |
| 2026-03-19 | Errico Thomas J. | X-InTheMoney | 19,252.00 | $6.43 | $123,790 |
| 2026-03-19 | Errico Thomas J. | X-InTheMoney | 22,803.00 | $4.35 | $99,193 |
| 2026-03-19 | Errico Thomas J. | X-InTheMoney | 22,803.00 | $4.35 | $99,193 |
| 2026-03-19 | Errico Thomas J. | X-InTheMoney | 19,252.00 | $6.43 | $123,790 |
| 2026-01-26 | Lev Joshua S. | A-Award | 25,000.00 | $0.00 | $0 |
| 2026-01-26 | Lev Joshua S. | A-Award | 2,889.00 | $0.00 | $0 |
| 2026-01-26 | Goldberger Daniel S | A-Award | 26,000.00 | $0.00 | $0 |
| 2026-01-26 | Goldberger Daniel S | A-Award | 20,375.00 | $7.47 | $152,201 |
| 2025-12-04 | Lev Joshua S. | S-Sale | 2,500.00 | $5.05 | $12,625 |
| 2025-12-02 | Goldberger Daniel S | P-Purchase | 1,000.00 | $4.84 | $4,840 |
| 2025-11-12 | Lev Joshua S. | S-Sale | 2,166.00 | $6.18 | $13,386 |
| 2025-09-10 | Bonfiglioli Elena | A-Award | 30,549.00 | $0.00 | $0 |
Narrative Economics
market-narrative step).